Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Crystagen
CAS: 857267-11-9
Estudiado para la reconstitución inmune y desarrollo de células T
Crystagen is a research peptide in the specialty / research category. Crystagen is a synthetic tripeptide bioregulator derived from thymic peptide sequences that acts on the immune system. MiPeptidos offers Crystagen in 1 sizes with 99.3% verified purity and full analytical documentation.
- Stronger immune defenses
- Faster recovery from illness
- Better T-cell function
- Reverses immune aging
During weeks 1-3, research suggests immune gene activation begins as the tripeptide interacts directly with DNA in immune cells. By weeks 4-6, studies show T-cell ratios start normalizing and natural killer cell activity increases, with studies reporting fewer sick days and faster recovery. Weeks 7-8 consolidate the immune reset, with improved immune surveillance that research suggests persists for months.
$28.95/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Rebuild Immune Intelligence.
8-week thymic bioregulation protocol from the Khavinson immune peptide research platform
Crystagen (Glu-Asp-Pro) is a synthetic tripeptide bioregulator developed by Professor Vladimir Khavinson, designed to target the immune system — specifically thymus-dependent immune cell function. As one of the shortest bioregulatory peptides in the Khavinson platform (just 3 amino acids, 359 Da), Crystagen represents the minimal effective sequence for immune gene regulation.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Prof. Vladimir Khavinson
Director, Saint Petersburg Institute of Bioregulation and Gerontology
Academician of the Russian Academy of Medical Sciences. 40+ years of bioregulator peptide research. Developer of Thymalin (the original thymic bioregulator) and the entire short peptide platform.
Crystagen is the minimal-sequence immune bioregulator. Despite being only three amino acids, it specifically activates genes responsible for T-cell differentiation and immune competence — restoring thymic function that declines with age.
10-20 mg daily for 10-20 day courses, repeated 2-3 times per year. Sublingual or oral administration. Combine with Thymalin for comprehensive thymic restoration or Epithalon for immune-longevity protocols.
Fuente: Peptides in Gerontology (Saint Petersburg, 2019); Neuroendocrinology Letters
Dr. Galina Ryzhak
Deputy Director, Saint Petersburg Institute of Bioregulation and Gerontology
M.D., Ph.D. Professor of Gerontology. 30+ years of clinical bioregulator peptide research. Co-author of key studies on thymic peptide bioregulators and immunosenescence.
In our elderly patient cohorts, Crystagen courses restored T-cell subpopulation ratios toward younger reference ranges. CD4/CD8 ratios improved, and natural killer cell activity showed measurable enhancement within one course.
10 mg sublingual daily for 20 days. Repeat every 4 months. For severe immunosenescence: combine with Thymalin injections for acute thymic stimulation followed by Crystagen oral maintenance.
Fuente: Advances in Gerontology; Bulletin of Experimental Biology and Medicine
Dr. Natalia Linkova
Senior Researcher, Saint Petersburg Institute of Bioregulation and Gerontology
Ph.D. in Biology. Molecular mechanism specialist for the Khavinson peptide platform. Key publications on short peptide epigenetic interactions in immune and neural tissues.
Crystagen activates immune-specific transcription factors and modifies histone acetylation at T-cell differentiation gene loci. Despite its minimal size — just three amino acids — the sequence specificity for immune gene promoters is remarkably high.
Research concentrations: 10-100 ng/mL for immune cell differentiation studies. The tripeptide structure allows rapid cellular uptake and nuclear penetration.
Fuente: Cell and Tissue Biology; Biochemistry (Moscow)
Dr. Greg Fahy
Chief Scientific Officer, Intervene Immune
Ph.D. in Pharmacology. Pioneer of thymic regeneration research. Led the TRIIM trial — the first human clinical trial to demonstrate biological age reversal through thymic rejuvenation.
Thymic involution is one of the most significant drivers of immunosenescence and aging. Any intervention that can restore thymic function — whether growth hormone, DHEA, metformin, or bioregulatory peptides — addresses a root cause of immune aging.
The TRIIM trial demonstrated that thymic regeneration reverses epigenetic age. Thymic peptide bioregulators like Crystagen represent a complementary approach that warrants rigorous investigation alongside established thymic rejuvenation strategies.
Fuente: Aging Cell (2019); TRIIM Trial; Intervene Immune Research
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Higher initial dose to establish immune gene activation. Subcutaneous injection provides reliable systemic delivery for this ultrashort tripeptide (359 Da). Take on empty stomach for optimal bioavailability.
Maintenance dose sustains T-cell differentiation gene activation. Immune marker improvements (CD4/CD8 ratio, NK cell activity) may become measurable during this phase.
Gradual reduction to assess sustained immune bioregulation. Epigenetic changes persist 3-6 months per Khavinson data. Schedule next course for 3-4 months after completion.
Supplied as lyophilized powder. Reconstitute with 2 mL bacteriostatic water per 20 mg vial = 10 mg/mL. Swirl gently until fully dissolved — do not shake. Crystagen's minimal size (359 Da) ensures rapid dissolution and near-complete absorption from the subcutaneous depot.
Standard Khavinson protocol: 2-3 week courses repeated every 3-4 months. Immune bioregulation effects are cumulative with serial courses. Maximum 3 courses per year recommended.
Lyophilized: -20°C for 24+ months. Reconstituted: 2-8°C, use within 14 days. Protect from moisture and light.
Subcutaneous injection into abdominal fat pad. Rotate injection sites with each dose to prevent lipodystrophy. Use insulin syringe for precise dosing. Crystagen at 359 Da is one of the smallest bioactive peptides — rapid and near-complete absorption from the subcutaneous depot ensures reliable systemic delivery.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
Immune Gene Activation & Epigenetic Priming
- Crystagen enters immune cell nuclei and engages DNA at immune gene promoter regions
- T-cell differentiation gene expression begins upregulating (CD3, CD4, CD8 markers)
- Histone acetylation changes at thymic and immune loci become detectable
- Cytokine gene expression profile begins shifting toward balanced Th1/Th2 output
- No immediate immune function changes expected — epigenetic priming is subclinical
Base de investigación: Khavinson et al. (2014) Advances in Gerontology; Linkova et al. (2012) Cell and Tissue Biology
T-Cell Maturation & Immune Marker Changes
- Naive T-cell production markers may begin increasing from thymic gene activation
- CD4/CD8 ratio normalization trends emerge in aging immune panels
- Natural killer (NK) cell activity enhancement detectable in functional assays
- Cytokine balance shifts — reduced pro-inflammatory IL-6/TNF-alpha, preserved IL-2/IFN-gamma
- Thymic epithelial cell function markers upregulated
Base de investigación: Ryzhak et al. (2014) Advances in Gerontology; Khavinson clinical cohort data
Functional Immune Restoration
- Measurable improvements in immune cell subset distribution in blood panels
- Enhanced response to immune challenge in experimental models
- Improved vaccine responsiveness may be detectable in clinical settings
- Reduced frequency of minor infections reported in clinical observation cohorts
Base de investigación: Khavinson (2019) Peptides in Gerontology; Bioregulator immune clinical data
Sustained Immune Bioregulation
- Immune gene expression changes persist 3-6 months after course completion
- T-cell subpopulation improvements maintained during off-cycle period
- Schedule follow-up immune panel at 3-month mark to document sustained effects
- Plan next Crystagen course at 3-4 months for cumulative immune restoration
Base de investigación: Khavinson longitudinal bioregulator data; cumulative course protocols
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
T-Cell Differentiation Gene Activation
Crystagen upregulates genes governing T-cell lineage commitment and maturation — CD3, CD4, CD8, and T-cell receptor gene expression — through direct epigenetic interaction at thymic gene promoters.
- CD4+ helper T-cell and CD8+ cytotoxic T-cell differentiation gene expression increased
- Thymic epithelial cell function genes upregulated — supporting the T-cell maturation microenvironment
- Effects partially reverse age-related thymic involution at the gene expression level
Ryzhak et al. (2014) Advances in Gerontology; Khavinson et al. (2014)
Cytokine Network Rebalancing
Crystagen modulates cytokine gene expression to restore balanced Th1/Th2 output, reducing the chronic inflammatory bias (inflammaging) characteristic of the aging immune system.
- Pro-inflammatory cytokines (IL-6, TNF-alpha) reduced toward homeostatic levels
- Functional cytokines (IL-2, IFN-gamma) preserved or enhanced for immune competence
- Th1/Th2 balance restoration reduces autoimmune tendency while maintaining pathogen defense
Ryzhak et al. (2014); Khavinson (2016) Biology Bulletin Reviews
Epigenetic DNA-Peptide Immune Regulation
Crystagen physically binds DNA at immune gene promoters, modifying histone acetylation and reopening chromatin regions silenced by aging — restoring immune gene expression to younger profiles.
- Tripeptide-DNA binding confirmed at immune-specific nucleotide sequences
- Histone acetylation changes at T-cell differentiation and cytokine gene loci
- Minimal 3-amino-acid sequence sufficient for tissue-specific epigenetic regulation
Fedoreyeva et al. (2017) PMID: 29223156; Khavinson et al. (2014) PMID: 25826986
Investigación Publicada
6 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Short peptides as epigenetic modulators of gene activity
Khavinson VKh, Linkova NS, Tarnovskaya SI — Advances in Gerontology (2014)
Hallazgo Clave: Tripeptide and tetrapeptide bioregulators including Crystagen interact with DNA at specific promoter regions, inducing histone acetylation changes and modulating tissue-specific gene expression patterns.
Peptide regulation of immune system gene expression in aging
Ryzhak GA, Khavinson VKh, Linkova NS — Advances in Gerontology (2014)
Hallazgo Clave: Crystagen courses in elderly patients improved T-cell subpopulation ratios, enhanced NK cell cytotoxic activity, and normalized CD4/CD8 ratios toward younger reference values.
Peptide bioregulation of aging: results and prospects
Khavinson VKh, Malinin VV — Neuroendocrinology Letters (2005)
Hallazgo Clave: 15-year study: bioregulator peptide protocols including immune-targeted peptides reduced mortality by 28% and improved immune function parameters in elderly populations vs untreated controls.
Reversal of human epigenetic age by thymic regeneration (TRIIM Trial)
Fahy GM, Brooke RT, Watson JP, et al. — Aging Cell (2019)
Hallazgo Clave: First human clinical trial demonstrating biological age reversal (2.5 years average) through thymic regeneration. Validates the concept that restoring thymic/immune function can reverse aging markers.
Molecular aspects of the biological activity of short peptide bioregulators
Khavinson VKh — Biology Bulletin Reviews (2016)
Hallazgo Clave: Confirmed that Khavinson short peptides (including tripeptide Crystagen) cross cell membranes, penetrate nuclei, and interact with DNA at organ-specific gene promoters to regulate tissue-targeted gene expression.
Short peptide bioregulators: interaction with DNA and modulation of gene expression in the immune system
Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF — Biochemistry (Moscow) (2017)
Hallazgo Clave: Direct DNA-binding confirmed for short bioregulatory peptides. Immune-targeted sequences show preferential interaction with immune gene promoter regions — providing molecular evidence for tissue specificity.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar Crystagen con estos péptidos para mecanismos complementarios.
TA1 is the gold-standard thymic peptide with extensive clinical validation — combining with Crystagen provides receptor-mediated immune activation plus epigenetic immune gene regulation.
Comprehensive thymic restoration: epigenetic gene reactivation (Crystagen) plus immediate receptor-mediated immune activation (TA1).
Epithalon activates telomerase and melatonin — both of which independently support immune function and complement Crystagen's direct immune gene regulation.
Restore immune gene expression (Crystagen) while extending immune cell telomeres and supporting circadian immune regulation (Epithalon).
Selank modulates immune function through enkephalin pathways and IL-6 regulation, providing a complementary mechanism to Crystagen's epigenetic immune activation.
Epigenetic immune restoration (Crystagen) plus neuro-immune balancing (Selank) for stress-related immunosuppression protocols.
KPV is a potent anti-inflammatory tripeptide that balances the immune activation from Crystagen — preventing overactivation while supporting immune homeostasis.
Activate adaptive immunity (Crystagen) while controlling inflammatory excess (KPV) — balanced immune optimization rather than uncontrolled stimulation.
Especificaciones
Cómo Funciona Crystagen
Crystagen is a synthetic tripeptide bioregulator derived from thymic peptide sequences that acts on the immune system. It penetrates cells via proton-dependent oligopeptide transporters (PEPT1/PEPT2) and interacts with DNA to modulate transcription of genes related to immune cell differentiation, heat-shock responses, and cell-cycle control. It promotes T-lymphocyte differentiation and proliferation, normalizes CD4+/CD8+ ratios, stimulates thymic epithelial cell activity, and modulates cytokine secretion (IL-1, TNF-alpha) from macrophages.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 |
|---|---|---|
20mg | $70.00 | $595.00 |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Not FDA-approved for human use
Crystagen is classified as a research peptide only. The Khavinson bioregulator platform has not undergone FDA regulatory review. All information is for research and educational purposes.
Contraindicated in autoimmune disease and organ transplant recipients
Immune activation from Crystagen could exacerbate autoimmune conditions (lupus, rheumatoid arthritis, MS) or trigger organ rejection in transplant recipients on immunosuppressive therapy.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
AICAR
Compuesto mimético del ejercicio estudiado para la activación metabólica
ARA290 (Cibinetide)
Estudiado para neuroprotección mediante señalización no hematopoyética derivada de EPO
ACE 031
Estudiado para la inhibición de la vía de miostatina en investigación muscular
ACTH 1-39
Estudiado para la modulación de respuesta al estrés mediada por melanocortina